Section Arrow
ANL.NASDAQ
- Adlai Nortye Ltd
Quotes are at least 15-min delayed:2026/05/11 17:22 EDT
After Hours
Last
 12.96
0 (0.00%)
Bid
12.96
Ask
13.06
High 12.96 
Low 12.96 
Volume 10 
Regular Hours (Closed)
Last
 12.96
-0.32 (-2.41%)
Day High 
14.3283 
Prev. Close
13.28 
1-M High
17.25 
Volume 
167.48K 
Bid
12.96
Ask
13.06
Day Low
12.76 
Open
13.12 
1-M Low
7.2 
Market Cap 
855.20M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 14.04 
20-SMA 14.48 
50-SMA 10.78 
52-W High 17.25 
52-W Low 0.8786 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.11/-0.23
Enterprise Value
856.33M
Balance Sheet
Book Value Per Share
-0.13
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
5.00M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.382+0.0318+9.08%-- 
After Hours 0.3753 -0.0067 -1.75%
GERNGeron Corp1.39------ 
After Hours 1.4 +0.01 +0.72%
TRAWTraws Pharma Inc2.02-0.16-7.34%2.43PE
After Hours 1.97 -0.05 -2.48%
MRNAModerna52.88-1.47-2.70%-- 
After Hours 53.3 +0.42 +0.79%
IOVAIovance Biotherapeutics3.7+0.08+2.21%-- 
After Hours 3.725 +0.025 +0.68%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.